IGF-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Growth hormone secretagogues or GH secretagogues (GHSs) are a class of drugs which act as secretagogues (i.e., induce the secretion) of growth hormone (GH). They include agonists of the ghrelin/growth hormone secretagogue receptor (GHSR), such as ghrelin (lenomorelin), pralmorelin (GHRP-2), GHRP-6, examorelin (hexarelin), ipamorelin, and ibutamoren (MK-677), and agonists of the growth hormone-releasing hormone receptor (GHRHR), such as growth hormone-releasing hormone (GHRH, somatorelin), CJC-1295, sermorelin, and tesamorelin. Many of them also induce the secretion of insulin-like growth factor 1 (IGF-1), as well as of other hypothalamic-pituitary hormones such as prolactin and cortisol. The main clinical application of these agents is the treatment of growth hormone deficiency.
== Registration of PKMM rejected == In 1950, the Federation of Malaya Government rejected the registration of the Malay Nationalist Party of Malaya (Parti Kebangsaan Melayu Malaya, PKMM) as a legitimate political party. PKMM had two wings, namely Angkatan Pemuda Insaf and Angkatan Wanita Sedar. Initially, PKMM did not have communist leanings. After Mokhtaruddin Lasso was elected as the first PKMM president in October 1946, this party was influenced with communism. The Young Malays Union (Kesatuan Melayu Muda, KMM) merged with PKMM, and Burhanuddin al-Helmy became the second PKMM president. Burhanuddin led PKMM toward the formation of Melayu Raya, a merger of Indonesia and Malaya. In December 1947, Ishak Haji Mohamed became the third PKMM president and PKMM switched from communism to nationalism. PKMM tended against United Malays National Organisation (UMNO) and colonisation. PKKM established the Pusat Tenaga Rakyat (PUTERA), a conglomeration of radical Malay Political Parties and then merged with the All-Malaya Council of Joint Action (AMCJA) which thoroughly opposed the 1948 Federation Agreement for the foundation of the Federation of Malaya. PKMM accused officials selected in the Federation of Malaya of being "puppets" of the "Colonial Office". For PKMM, there was no basis in "preparing Malaya as a democratic government".
Because of the unique social setting of London medicine, anesthesia had become its own speciality there by the end of the nineteenth century, while in the rest of the United Kingdom and most of the world anesthesia remained under the purview of the surgeon who would assign the task to a junior doctor or nurse. After Austrian diplomat Karl von Scherzer brought back sufficient quantities of coca leaves from Peru, in 1860 Albert Niemann isolated cocaine, which thus became the first local anesthetic. In 1871, the German surgeon Friedrich Trendelenburg (1844–1924) published a paper describing the first successful elective human tracheotomy to be performed for the purpose of administration of general anesthesia. In 1880, the Scottish surgeon William Macewen (1848–1924) reported on his use of orotracheal intubation as an alternative to tracheotomy to allow a patient with glottic edema to breathe, as well as in the setting of general anesthesia with chloroform. All previous observations of the glottis and larynx (including those of Manuel García, Wilhelm Hack and Macewen) had been performed under indirect vision (using mirrors) until 23 April 1895, when Alfred Kirstein (1863–1922) of Germany first described direct visualization of the vocal cords. Kirstein performed the first direct laryngoscopy in Berlin, using an esophagoscope he had modified for this purpose; he called this device an autoscope. The death of Emperor Frederick III (1831–1888) may have motivated Kirstein to develop the autoscope.
=== Peptide nucleic acids (PNA) === Peptide nucleic acids are synthetic oligonucleotides that resist protease degradation and are used to induce repair at site-specific triplex formation regions on DNA genomic sites. PNAs are able to bind with high affinity and sequence specificity to a complementary DNA sequence through Watson-Crick base-pairing and are able to form triple helices through parallel orientation Hoogsteen bonds, with the PNA facing the 5'-end of the DNA strand. The PNA-DNA triplex is stable because PNAs consist of a neutrally charged pseudopeptide backbone which binds to the double stranded DNA (dsDNA) sequence. Similar to homopyrimidine in TFOs, homopyrimidine in PNAs is able to form a bond with the complementary homopurine in the target sequence of dsDNA. These DNA analogues are able to bind to dsDNA by exploiting ambient DNA conditions and different predicting modes of recognition. This is different from TFOs which bind though the major groove recognition of the dsDNA. One of the predicting modes of recognition used for recognition is through a duplex invasion. Within mixed A–T/G–C dsDNA sequence is targeted by a pair of pseudo-complementary (pc) PNAs which are able to bind to dsDNAs via double invasion through the simultaneous formation of diaminopurine (D) and thiouracil (Us) which substitute for adenine and thymine, respectively. The pc PNA pair form a D-T and Us -A and G-C or C-G Watson-Crick paired PNA-DNA helix with each of complementary DNA strands.
Sources: en.wikipedia.org
Sulanemadlin (development code ALRN-6924) is an experimental drug for the treatment of cancer. It is under development by Aileron Therapeutics, and has been studied in clinical trials for myelodysplastic syndrome and acute myeloid leukemia. Sulanemadlin is a stapled peptide that mimics the N-terminal domain of p53, a tumor suppressor protein. As such, it binds to MDM2 and MDMX, leading to tumor cell apoptosis.
This drastically revamped King Crimson had no plans to record in the studio, focusing instead on playing "reconfigured" versions of past material live. According to Levin, the band "were instructed/advised by Robert Fripp to look at the older classic King Crimson material as if we had written it. And so we did that with a lot of older material that the band had done before the '80s. We didn't actually cover that much of the '80s material outside of a few songs." For the most part, this approach would remain consistent for the remainder of the band's lifetime. In early 2014, the band's repertoire included songs from the run of albums between In the Court of the Crimson King and Larks' Tongues in Aspic for the first time since 1974, as well as reviving song material from Red. No songs with vocals by Belew were included in the setlist, although some instrumentals from his tenure were played. Some material from A Scarcity of Miracles was also incorporated into the band's repertoire. After rehearsing in England, King Crimson toured North America from 9 September to 6 October. Recordings from the Los Angeles dates were released as Live at the Orpheum; this included the newly-written instrumentals "Banshee Legs Bell Hassle" and "Walk On: Monk Morph Chamber Music". Tours of Europe, Canada, and Japan followed in the later half of 2015. Brand-new songs mainly written by Fripp and Jakszyk were debuted at the concerts, as well as drum showcases.
Iranians have one of the highest per capita rates of tea consumption in the world. Châikhânes (teahouses) are common in Iran. Iranian tea is typically served in traditional Iranian glasses with a traditional saucer and teaspoon. Tea is cultivated in northern Iran along the shores of the Caspian Sea. In Burma (Myanmar), tea is consumed not only as hot drinks, but also as sweet tea and green tea known locally as laphet-yay and laphet-yay-gyan, respectively. Pickled tea leaves, known locally as lahpet, are a national delicacy. Pickled tea is usually eaten with roasted sesame seeds, crispy fried beans, roasted peanuts and fried garlic chips. In Mali, gunpowder tea is served in series of three, starting with the highest oxidisation or strongest, unsweetened tea, locally referred to as "strong like death", followed by a second serving, where the same tea leaves are boiled again with some sugar added ("pleasant as life"), and a third one, where the same tea leaves are boiled for the third time with yet more sugar added ("sweet as love"). Green tea is the central ingredient of a distinctly Malian custom, the "grin", an informal social gathering that cuts across social and economic lines, starting in front of family compound gates in the afternoons and extending late into the night, and is widely consumed in Bamako and other large urban areas. In the United States, 80% of tea is consumed as iced tea. Sweet tea is native to the southeastern U.S. and is iconic in its cuisine due to its refreshing temperature and large amount of sweetener.
Sources: en.wikipedia.org
"Layne was really responsible for giving me the confidence to become more of a singer. He'd say, 'You wrote this song, this means something to you, sing it.' He kicked my ass out of the nest. Over the years I continued to grow, and Layne started to play guitar, and we inspired each other". Since 2002, Seattle has hosted an annual tribute concert for Staley on his birthday. Venues such as the Moore Theatre, The Showbox The Fenix, and The Crocodile have hosted the event. The show proceeds benefit the Layne Staley Memorial Fund. Staley ranked at No. 27 on Hit Parader magazine's list of "Heavy Metal's All-Time Top 100 Vocalists" published in the November 2006 issue, and at No. 42 on Complex's magazine list of "The 50 Best Lead Singers of All Time" in 2012. Staley was an inspiration for the title of Metallica's 2008 album, Death Magnetic. The band recorded a song in tribute to him, titled "Rebel of Babylon". In 2009, Alice in Chains released their first studio album in 14 years, Black Gives Way to Blue, with Cantrell and then-new vocalist and rhythm guitarist William DuVall sharing lead vocals. The title track is a tribute to Staley. Cantrell invited Elton John to join Alice in Chains and pay tribute to Staley playing the piano in "Black Gives Way to Blue", the closing song in the album. The song was written and sung by Cantrell, who described it as the band's goodbye to Staley. The first concert that Staley attended was Elton John's and he was blown away by it.
Specimens, which can vary from a full human body to a small piece of an animal organ, are known as 'plastinates'. Once plastinated, the specimens and bodies are further manipulated and positioned prior to curing (hardening) of the polymer chains.
== History == Historical descriptions of possible PMOS symptoms date to ancient Greece, where Hippocrates described women with "thick, oily skin and absence of menstruation." The earliest known description of what is now recognized as PMOS dates from 1721 in Italy, which described "Young married peasant women, moderately obese and infertile, with two larger than normal ovaries, bumpy, shiny and whitish, just like pigeon eggs". Polycystic ovaries were likely first formally described in 1844 by the French doctor Achille Chereau. In 1935, American gynecologists Irving F. Stein and Michael L. Leventhal published a report linking polycystic ovaries to hirsutism, infertility, and lack of periods. The report also hypothesised that PMOS results from endocrine dysfunction, initiating research into its hormonal causes and giving rise to the term Stein–Leventhal syndrome. By the 1980s, the metabolic side of PMOS started to be studied, before the start of genetics research in the 1990s.
=== Other effects === Progesterone also has a role in skin elasticity and bone strength, in respiration, in nerve tissue and in female sexuality, and the presence of progesterone receptors in certain muscle and fat tissue may hint at a role in sexually dimorphic proportions of those. During pregnancy, progesterone is said to decrease uterine irritability. During pregnancy, progesterone helps to suppress immune responses of the mother to fetal antigens, thus preventing rejection of the fetus. Progesterone raises epidermal growth factor-1 (EGF-1) levels, a factor often used to induce proliferation of stem cells, and used to sustain stem cell cultures. Progesterone increases core temperature (thermogenic function) during ovulation. Progesterone reduces spasm and relaxes smooth muscle. Bronchi are widened and mucus regulated. (PRs are widely present in submucosal tissue.) Progesterone acts as an anti-inflammatory agent and regulates the immune response. Progesterone reduces gallbladder activity. Progesterone normalizes blood clotting and vascular tone, zinc and copper levels, cell oxygen levels, and use of fat stores for energy. Progesterone may affect gum health, increasing risk of gingivitis (gum inflammation). Progesterone appears to prevent endometrial cancer (involving the uterine lining) by regulating the effects of estrogen. Progesterone plays an important role in the signaling of insulin release and pancreatic function, and it may affect the susceptibility to diabetes or gestational diabetes.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.